Biblio
Export 2680 results:
Author Title Type [ Year
Filters: First Letter Of Keyword is A [Clear All Filters]
“Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 3, pp. 1261-1274, 2024.
, “The RESIST Study: Examining Cognitive Change in Rheumatoid Arthritis Patients with Mild Cognitive Impairment Being Treated with a TNF-Inhibitor Compared to a Conventional Synthetic Disease-Modifying Anti-Rheumatic Drug.”, J Alzheimers Dis, vol. 99, no. 1, pp. 161-175, 2024.
, “The RESIST Study: Examining Cognitive Change in Rheumatoid Arthritis Patients with Mild Cognitive Impairment Being Treated with a TNF-Inhibitor Compared to a Conventional Synthetic Disease-Modifying Anti-Rheumatic Drug.”, J Alzheimers Dis, vol. 99, no. 1, pp. 161-175, 2024.
, “The RESIST Study: Examining Cognitive Change in Rheumatoid Arthritis Patients with Mild Cognitive Impairment Being Treated with a TNF-Inhibitor Compared to a Conventional Synthetic Disease-Modifying Anti-Rheumatic Drug.”, J Alzheimers Dis, vol. 99, no. 1, pp. 161-175, 2024.
, “The Role of Impaired Receptor Trafficking in Mediating the Pathological Effects of APOE4 in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 2, pp. 753-775, 2024.
, “The Role of Impaired Receptor Trafficking in Mediating the Pathological Effects of APOE4 in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 2, pp. 753-775, 2024.
, “The Role of Impaired Receptor Trafficking in Mediating the Pathological Effects of APOE4 in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 2, pp. 753-775, 2024.
, “The Role of Impaired Receptor Trafficking in Mediating the Pathological Effects of APOE4 in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 2, pp. 753-775, 2024.
, “The Role of Impaired Receptor Trafficking in Mediating the Pathological Effects of APOE4 in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 2, pp. 753-775, 2024.
, “Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study.”, J Alzheimers Dis, vol. 98, no. 1, pp. 265-274, 2024.
, “Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study.”, J Alzheimers Dis, vol. 98, no. 1, pp. 265-274, 2024.
, “A Scoping Review of Alzheimers Disease Hypotheses: An Array of Uni- and Multi-Factorial Theories.”, J Alzheimers Dis, vol. 99, no. 3, pp. 843-856, 2024.
, “Senescence Targeting Methods Impact Alzheimer's Disease Features in 3xTg Mice.”, J Alzheimers Dis, vol. 97, no. 4, pp. 1751-1763, 2024.
, “Senescence Targeting Methods Impact Alzheimer's Disease Features in 3xTg Mice.”, J Alzheimers Dis, vol. 97, no. 4, pp. 1751-1763, 2024.
, “Sex and Sleep Disruption as Contributing Factors in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 1, pp. 31-74, 2024.
, “Sex and Sleep Disruption as Contributing Factors in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 1, pp. 31-74, 2024.
, “Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. 1, pp. 321-332, 2024.
, “Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. 1, pp. 321-332, 2024.
, “Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. 1, pp. 321-332, 2024.
, “Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. 1, pp. 321-332, 2024.
, “Sildenafil as a Candidate Drug for Alzheimer's Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons.”, J Alzheimers Dis, vol. 98, no. 2, pp. 643-657, 2024.
, “Sildenafil as a Candidate Drug for Alzheimer's Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons.”, J Alzheimers Dis, vol. 98, no. 2, pp. 643-657, 2024.
, “Sleep Biomarkers for Predicting Cognitive Decline and Alzheimer's Disease: A Systematic Review of Longitudinal Studies.”, J Alzheimers Dis, vol. 97, no. 1, pp. 121-143, 2024.
, “Small RNA Profiles of Brain Tissue-Derived Extracellular Vesicles in Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. s2, pp. S235-S248, 2024.
, “Small RNA Profiles of Brain Tissue-Derived Extracellular Vesicles in Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. s2, pp. S235-S248, 2024.
,